Penn Medicine | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Michael G. Fradley, MD, discusses real-world data on atrial fibrillation incidence and its cardiovascular and health care impact in CLL.

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.

Dr Reiss Binder discusses the significance of the FDA approval of daraxonrasib for pretreated metastatic pancreatic adenocarcinoma.

Drs Aredo and Bleiberg reflect on the experiences and relationships that shaped their transitions from fellowship into their first faculty positions in thoracic oncology.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

Kim A. Reiss Binder, MD, notes the significance of the approval of daraxonrasib for metastatic PDAC and how it positions a new era for RAS-targeted drugs.

The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.

Adam D. Cohen, MD, discusses the mechanism of action of cevostamab in relapsed/refractory multiple myeloma.

Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

Adam D. Cohen, MD, discusses future research directions for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses phase 1 efficacy data for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.

Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.

Stefan K. Barta, MD, MS, discusses how to distinguish MAR from mycosis fungoides lesions in cutaneous T-cell lymphoma.

Stefan K. Barta, MD, MS, discusses the CTCL subtype mycosis fungoides, common adverse effects, and optimal treatment approaches.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

Igor Makhlin, MD, notes the imaging modalities used in metastatic breast cancer and highlights FES-PET/CT as a specific modality for ER-positive disease.

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

Igor Makhlin, MD, discusses the evolving role of FES-PET/CT as a tool to aid in the diagnosis and management of estrogen receptor–positive breast cancer.

Sophia O’Brien, MD, discusses the role of nuclear medicine in lobular breast cancer diagnosis and staging, as well as use criteria for FES-PET/CT.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.